Methods and compositions for treatment of multi-drug resistant tumors
AssigneeSun Yat-Sen University
InventorsYijun HUANG, Danyang LIU, Juncheng PAN, Yang HU, Zhu ZHU
Life of this patent
Estimating the term…
Abstract
Methods for treatment of a multi-drug resistant (MDR) tumor in a subject are disclosed. The methods comprise administering to the subject in need of treatment a therapeutically effective amount of an anti-mycoplasma agent and/or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy. Relevant pharmaceutical compositions, kits, uses are also disclosed.
Claims23
A method for treatment of a multi-drug resistant tumor in a subject, wherein the multi-drug resistant tumor is resistant to at least two classes of chemotherapeutic agents selected from an alkylating agent, an antibiotic, an antimetabolite, an immunotherapy, a hormone or hormone antagonist, a taxane, a retinoid, an alkaloid, an antiangiogenic agent, a topoisomerase inhibitor, a kinase inhibitor, a targeted signal transduction inhibitor, and a biological response modifier, the method comprising administering to the subject in need of treatment a therapeutically effective amount of an anti-mycoplasma agent and/or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, prior to, at the same time with, or after chemotherapy.
The method of claim 45, wherein the P37 inhibitor is selected from an antisense oligomer selected from dsRNA, siRNA, and shRNA directed against P37 protein;
- and an P37 antibody or a fragment thereof.
The method of claim 45, wherein the Annexin A2 inhibitor is selected from an antisense oligomer selected from dsRNA, siRNA, and shRNA directed against Annexin A2 protein;
- and an Annexin A2 antibody or a fragment thereof.
(canceled)
(canceled)
A pharmaceutical composition or kit for treatment of a multi-drug resistant (MDR) tumor in a subject, comprising, in unit dosage form, a therapeutically effective amount of an anti-mycoplasma agent and/or an agent blocking the interaction between membrane protein P37 of mycoplasma and Annexin A2 of host cells of the subject, a therapeutically effective amount of a chemotherapeutic agent, and a pharmaceutically acceptable carrier, wherein the chemotherapeutic agent is selected from an alkylating agent, an antibiotic, an immunotherapy, a hormone or hormone antagonist, a taxane, a retinoid, an alkaloid, an antiangiogenic agent, a topoisomerase inhibitor, a kinase inhibitor, a targeted signal transduction inhibitor, and a biological response modifier.
-46. (canceled)
Dependencies are inferred from the claim text.